Lumos Diagnostics Secures 43 Site WellStreet Expansion Targeting 163 Locations
Lumos Diagnostics secures 43-site expansion with WellStreet Urgent Care
Lumos Diagnostics has secured an expanded agreement with WellStreet Urgent Care to roll out its FebriDx rapid respiratory test across 43 additional locations following the success of an initial pilot site. The expansion, announced on 14 April 2026, positions the Company to potentially deploy FebriDx across WellStreet’s entire 163-location network over the next 6–12 months, representing approximately 1.1 million acute respiratory presentations annually.
The multi-site rollout follows a pilot programme launched in October 2025 at WellStreet’s Piedmont Healthcare joint venture location in Atlanta, Georgia, which processes approximately 50 patients per day presenting predominantly with acute respiratory infections. The pilot’s success, combined with the US Food and Drug Administration granting CLIA waiver status for FebriDx on 27 March 2026, enabled this rapid expansion.
The current phase will deploy FebriDx across three distinct geographic regions over the next two months:
- Fayetteville District: 8 locations
- Georgia East District: 7 locations
- Michigan market: 28 locations
Under the expanded programme, WellStreet has implemented a standing order protocol where every patient presenting with acute respiratory infection symptoms will be offered FebriDx testing. This commercial validation represents a significant milestone for Lumos Diagnostics, demonstrating the test’s operational viability in high-volume urgent care settings and establishing a pathway for broader US market penetration.
When big ASX news breaks, our subscribers know first
How point-of-care respiratory testing works
FebriDx is a rapid diagnostic test that differentiates between bacterial and non-bacterial respiratory infections, delivering results in approximately 10 minutes. The technology addresses a critical gap in urgent care workflows by providing actionable clinical data before a healthcare provider enters the examination room.
Under WellStreet’s implementation model, FebriDx testing occurs as part of the initial patient intake process for those presenting with respiratory symptoms. This workflow integration means test results are available to inform treatment decisions during the consultation rather than requiring follow-up or delayed prescribing.
The test supports antibiotic stewardship by helping clinicians identify which respiratory infections are likely bacterial (requiring antibiotic treatment) versus viral or non-bacterial (where antibiotics would be ineffective). This clinical differentiation is particularly valuable in urgent care settings, where providers must make rapid treatment decisions without the luxury of extended diagnostic timelines.
Dr Brian S. Bobb, Senior Medical Officer and SVP, WellStreet Urgent Care
“Point-of-care diagnostics like FebriDx give our providers actionable data before they even enter the exam room — that kind of precision directly supports better patient outcomes and antibiotic stewardship.”
For urgent care operators, the technology creates value through improved patient throughput (faster diagnosis enables quicker treatment decisions) and enhanced treatment accuracy (reduced inappropriate antibiotic prescribing). These operational benefits drive adoption by addressing core business challenges in high-volume acute care environments.
Commercial implications for Lumos Diagnostics
The expansion across 43 locations in three distinct US regions generates significantly increased test volumes compared to the single-site pilot, providing Lumos Diagnostics with broader reimbursement data and geographic market presence. This expanded footprint strengthens the Company’s position in future contracting discussions with both healthcare providers and commercial payors.
Increased testing volumes across diverse patient populations and payor mixes build the evidence base required for negotiating with additional urgent care networks and health systems. The WellStreet deployment provides operational case studies demonstrating workflow integration, clinician adoption, and patient outcomes — key criteria health systems evaluate when considering new diagnostic technologies.
| Phase | Locations | Region | Status |
|---|---|---|---|
| Initial pilot | 1 | Atlanta/Piedmont | Complete |
| Current expansion | 43 | Fayetteville/Georgia East/Michigan | Rolling out |
| Full network potential | 163 | US-wide | 6–12 months |
The geographic diversity of the current rollout is strategically significant. Deploying across Michigan, Georgia, and North Carolina markets exposes FebriDx to different payor environments, patient demographics, and regional prescribing patterns. This multi-market validation strengthens the commercial case for adoption by additional provider networks operating in similar or adjacent geographies.
CEO Doug Ward stated the expansion “represents an important next step for FebriDx, by increasing test volume across a broader geographic footprint, improving payor visibility, and strengthening our position in future contracting discussions with potential new providers.”
Strategic positioning in US urgent care market
The 27 March 2026 CLIA waiver represents a critical regulatory milestone that removes adoption barriers for urgent care settings. CLIA-waived tests can be performed in clinical settings without the complex laboratory certification requirements applied to moderate or high-complexity tests, making them operationally viable for urgent care centres focused on rapid patient throughput.
WellStreet Urgent Care operates through partnership models with major health systems including Piedmont Healthcare, Corewell Health (formerly Beaumont), University Hospitals, and Prisma Health. Founded in 2011, the network expanded from seven locations in its first year to 163 locations by 2026 through this multi-system partnership approach. For Lumos Diagnostics, this provides access to established urgent care infrastructure across multiple US regions without requiring direct health system negotiations.
The partnership model also creates potential for organic expansion. As WellStreet continues forming joint ventures with additional health systems, FebriDx adoption may extend to new geographies through existing commercial relationships rather than requiring separate provider agreements.
Dr Michael Duchynski, Chief Operating Officer and Chief Medical Officer, WellStreet Urgent Care
“Expanding FebriDx across our network is a natural next step — it supports our commitment to evidence-based care and helps ensure every patient gets the right treatment, faster.”
WellStreet’s multi-partner structure means successful deployment across the current 43 locations will be visible to health systems evaluating point-of-care diagnostics, potentially accelerating adoption conversations with providers operating outside the WellStreet network.
The next major ASX story will hit our subscribers first
What comes next for FebriDx adoption
Following completion of the current 43-location rollout over the next two months, Lumos Diagnostics expects WellStreet to launch FebriDx across the remaining 120 locations within 6–12 months. This phased approach allows operational learnings from the expanded pilot to inform full network deployment whilst maintaining commercial momentum.
The timeline provides visibility on near-term commercial growth, with the Company progressing from single-site validation to potential full-network deployment of 163 locations within approximately 18 months of the initial pilot launch. This pilot-to-scale pathway demonstrates both product-market fit and operational scalability.
Key milestones and timelines include:
- Next two months: Deployment across 43 locations in Fayetteville, Georgia East, and Michigan districts
- 6–12 months: Potential rollout to remaining 120 WellStreet locations
- Ongoing: Strengthened contracting discussions with additional healthcare providers and payors based on expanded volume data
CEO Ward’s reference to “improving payor visibility” highlights a critical commercial dynamic. Health insurers and managed care organisations require volume data from diverse patient populations before negotiating reimbursement rates or establishing in-network testing protocols. The WellStreet expansion generates this evidence base whilst the Company pursues additional provider partnerships.
Success across the WellStreet network creates replicable case studies for discussions with competing urgent care operators and health systems seeking similar clinical workflow improvements. The standing order protocol implemented by WellStreet provides a scalable deployment model that reduces implementation barriers for subsequent provider partners.
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving news breaks across healthcare, tech, finance and beyond.